Department of Periodontology, College of Dentistry, University of Florida, Gainesville, FL, USA.
Department of Periodontology, Dental Research Division, Guarulhos University, Guarulhos, Sao Paulo, Brazil.
J Periodontol. 2021 Feb;92(2):196-204. doi: 10.1002/JPER.19-0714. Epub 2020 Aug 14.
Previous studies have suggested an association between taking antidepressants and dental implant failure. This study aimed to investigate the association of different antidepressant classes with dental implant failure.
This retrospective study included patients that received dental implants at the University of Florida from 2011 to 2016. The variables of implant failure, antidepressant use and classes (selective serotonin reuptake inhibitors [SSRI], serotonin-norepinephrine reuptake inhibitors [SNRI], tricyclic antidepressants [TCA], atypical antidepressants [AA], and monoamine oxidase inhibitors [MAOI]), age, sex, smoking, mild systemic diseases, and implant location were obtained from patients' records. Odds ratio (OR) and confidence interval (CI) of implant failure in patients taking different antidepressant classes, in relationship to non-antidepressant users, were estimated, and the influence of multiple variables on implant failure were investigated.
A total of 771 patients and 1,820 implants were evaluated. The statistically significant predictors for implant failure included smoking (OR = 5.221), use of antidepressants (OR = 4.285), posterior maxilla location (OR = 2.911), mild systemic disease (OR = 2.648), and age (OR = 1.037) (P <0.05). The frequency of implant failure was 33.3% in TCA users, 31.3% in SNRI users, 6.3% in SSRI users, 5.2% in Atypical antidepressant users, and 3.9% in non-users. Significant associations were observed between the use of SNRI (OR: 11.07; 95% CI: 3.265 to 33.82) and TCA (OR: 12.16; 95% CI: 1.503 to 71.58) and implant failure (P <0.05).
Users of antidepressants were at higher risk of implant failure than non-users. Patients taking SNRI and TCA were at the highest risk of implant loss, when compared with non-users. Conclusions about TCA, however, are based on a limited number of cases.
先前的研究表明，服用抗抑郁药与牙种植体失败之间存在关联。本研究旨在调查不同抗抑郁药类别与牙种植体失败的关系。
这是一项回顾性研究，纳入了 2011 年至 2016 年在佛罗里达大学接受牙种植体的患者。从患者的记录中获得了种植体失败、抗抑郁药使用情况和类别（选择性 5-羟色胺再摄取抑制剂[SSRIs]、5-羟色胺-去甲肾上腺素再摄取抑制剂[SNRIs]、三环抗抑郁药[TCA]、非典型抗抑郁药[AA]和单胺氧化酶抑制剂[MAOIs]）、年龄、性别、吸烟、轻度系统性疾病和种植体位置等变量。估计了服用不同抗抑郁药类别患者的种植体失败的比值比（OR）和置信区间（CI），并调查了多个变量对种植体失败的影响。
共评估了 771 名患者和 1820 枚种植体。种植体失败的统计学显著预测因子包括吸烟（OR=5.221）、使用抗抑郁药（OR=4.285）、上颌后牙区（OR=2.911）、轻度系统性疾病（OR=2.648）和年龄（OR=1.037）（P<0.05）。TCA 使用者的种植体失败频率为 33.3%，SNRI 使用者为 31.3%，SSRI 使用者为 6.3%，非典型抗抑郁药使用者为 5.2%，非使用者为 3.9%。SNRI 的使用（OR：11.07；95%CI：3.265 至 33.82）和 TCA 的使用（OR：12.16；95%CI：1.503 至 71.58）与种植体失败之间存在显著关联（P<0.05）。
与非使用者相比，使用抗抑郁药的患者种植体失败的风险更高。与非使用者相比，服用 SNRI 和 TCA 的患者种植体丢失的风险最高，然而，关于 TCA 的结论是基于有限的病例数得出的。
